Acquisition by Fairmount Funds Management Llc of 1600000 shares of Viridian Therapeutics at 18.75 subject to Rule 16b-3

PRRUF Stock  USD 0.20  0.00  0.00%   
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
  
Filed transaction by Viridian Therapeutics Director, 10 Percent Owner . Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 1600000 common stock at 18.75 of Viridian Therapeutics by Fairmount Funds Management Llc on 8th of November 2024. This event was filed by Viridian Therapeutics with SEC on 2024-09-13. Statement of changes in beneficial ownership - SEC Form 4

Immutep Fundamental Analysis

We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Immutep is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Immutep Limited Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.

Peers

Immutep Related Equities

IMMXImmix Biopharma   5.48   
0%
15.0%
CRNXCrinetics Pharmaceuticals   5.21   
0%
14.0%
DSGNDesign Therapeutics   4.23   
0%
11.0%
APLTApplied Therapeutics   2.48   
0%
6.0%
AADIAadi Bioscience   1.67   
0%
4.0%
CYTKCytokinetics   0.30   
0%
1.0%
CGEMCullinan Oncology   0.24   
1.0%
0%
ALVRAllovir   0.73   
2.0%
0%
GPCRStructure Therapeutics   1.30   
3.0%
0%
CDTXCidara Therapeutics   1.58   
4.0%
0%
VRDNViridian Therapeutics   1.96   
5.0%
0%
ENVBEnveric Biosciences   2.47   
6.0%
0%
ZNTLZentalis Pharmaceuticals   3.05   
8.0%
0%
CTMXCytomX Therapeutics   3.31   
9.0%
0%
ALXOAlx Oncology   3.80   
10.0%
0%
ELEVElevation Oncology   4.00   
11.0%
0%
SANASana Biotechnology   5.65   
15.0%
0%
ZURAZura Bio   9.71   
26.0%
0%
OLMAOlema Pharmaceuticals   12.76   
35.0%
0%
SLNSilence Therapeutics   12.84   
35.0%
0%
ADCTADC Therapeutics   36.21   
100.0%
0%

Complementary Tools for Immutep Pink Sheet analysis

When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments